Jones Day
Firm overview:
Jones Day offers a broad, integrated patent practice in the US, covering both non-contentious and contentious matters. The firm has significant experience in developing and prosecuting global patent portfolios for clients in the life sciences industry, and represents some of the major companies in the space.
Lawyers at the firm have tried patent cases in forums such as Texas, Delaware, California, Virginia, New Jersey, Pennsylvania and Washington, DC, as well as before the International Trade Commission (ITC) and the Patent Trial and Appeal Board (PTAB). The team also has appellate and cross-border experience in patent matters.
Team overview:
New York partner Jennifer Chheda “has a lot of experience in biologics”, says a peer. Chheda’s practice focuses on procuring and enforcing patents relating to biologics and small molecules, and she has developed and managed worldwide patent portfolios for clients in the life sciences industry.
San Diego lawyer Anthony Insogna, the Intellectual Property practice leader, is the client contact for the firm’s patents practice. Insogna and his teams have achieved numerous patent litigation victories, including a $107.5 million jury award in Puma Biotechnology v AstraZeneca, a $2.54 billion jury award for Idenix (Merck & Co) against Gilead, and successful enforcement and defence of patents for Kyowa Kirin’s Potelligent platform technology, which also created new law under Section 1782.
Insogna’s advisory experience includes driving portfolio strategy for numerous pharmaceutical products and his IP strategies have been employed in high-value litigation and M&A matters, including Dainippon Sumitomo Pharma’s $2.6 billion acquisition of Sepracor (now Sunovion) and Pfizer’s $1.3 billion acquisition of Esperion.
In 2025, additions to the team included experienced patent litigators Edward Reines and Derek Walter, who joined from Weil.
Yi Han Dulkeith, who holds a PhD and focuses her practice on global patent portfolio development, patent prosecution and other related matters, left the firm to join Steptoe.
Key matters:
- Global patent portfolio development for AI-powered drug discovery company
Jones Day is representing MindRank AI, an artificial intelligence (AI)-powered drug discovery company, in the development of global patent portfolios related to clinical-stage small molecule therapeutics and methods for the treatment of various metabolic disorders.
- Advisory work and portfolio development for AbbVie
Jones Day provides strategic IP counselling to AbbVie regarding its Clostridium botulinum neurotoxin portfolio, including BOTOX. The team also represents AbbVie in the development and prosecution of global patent portfolios related to SKYRIZI, an interleukin-23 (IL-23) inhibitor for treating inflammatory conditions.
- Motorola Solutions v Stellar
Jones Day represented Motorola Solutions in a patent dispute with Stellar, which sued Motorola for alleged patent infringement. Motorola filed inter partes reviews challenging the validity of the patents-in-suit.
The PTB initially instituted review; however this was vacated following a Director Review request from Stellar.
Motorola petitioned the Federal Circuit for a writ of mandamus, seeking to reinstate the PTAB’s original decision. This was denied in November 2025.
- CODA Development et al v Goodyear Tire & Rubber Company et al
Jones Day successfully represented Goodyear and employees in litigation where they were accused of misappropriating trade secrets relating to self-inflating tire technology and incorporating the technology into several US patents.
A victory for Goodyear on all the claims was affirmed by the Federal Circuit in December 2025.
- Federal Circuit win for Medtronic
The team overturned a $125 million patent infringement judgment at the Federal Circuit for Medtronic involving its replacement heart valve and method of implantation. The Federal Circuit ordered judgment of non-infringement for Medtronic in July 2025.
Jones Day successfully argued that Colibri Heart Valve’s assertion of infringement under patent law's doctrine of equivalents was barred by Colibri's arguments and amendments during the prosecution of its patent application.
Clients:
Clients: AbbVie, Hisense Visual Technology, Medtronic, MindRank AI, Motorola, Nikon, Qualcomm, RJ Reynolds
